retatrutide phase 2 trial type 2 diabetes weight loss 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Lilly's triple agonist, retatrutide, demonstrated

I actually had a stomach

Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025) reported that participants taking 12mg of Retatrutide over 68 weeks lost an average of 28.7% of their body weight, the highest result ever reported at that stage for any obesity-related compound

The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials

LISTEN | What's going on with peptides?: The FDA, in documents for the meeting, said many of the peptides lack adequate human safety and efficacy data

The glucagon-driven thermogenesis adds to this baseline, creating a larger total caloric deficit